An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Tempest Therapeutics, Inc. (Nasdaq: TPST) granted an employee nonqualified stock options to purchase 5,400 shares under the 2023 Inducement Plan. The options will vest over four years, with 25% on the first anniversary and monthly thereafter, contingent on continued employment.
Tempest Therapeutics, Inc. (Nasdaq: TPST) ha concesso a un dipendente delle opzioni su azioni non qualificate per l'acquisto di 5.400 azioni nell'ambito del Piano di Induzione 2023. Le opzioni matureranno nel corso di quattro anni, con il 25% alla prima ricorrenza annuale e poi mensilmente, a condizione di un impiego continuativo.
Tempest Therapeutics, Inc. (Nasdaq: TPST) otorgó a un empleado opciones de compra de acciones no calificadas para adquirir 5.400 acciones bajo el Plan de Inducción 2023. Las opciones se adquirirán a lo largo de cuatro años, con un 25% en el primer aniversario y mensualmente a partir de entonces, sujeto a la continuidad del empleo.
Tempest Therapeutics, Inc. (나스닥: TPST)는 2023 유인 계획에 따라 직원에게 5,400주의 비자격 주식 옵션을 부여했습니다. 이 옵션은 4년에 걸쳐 획득되며, 첫 번째 주년에 25%, 그 후 매월 계속되는 고용 조건에 따라 부여됩니다.
Tempest Therapeutics, Inc. (Nasdaq : TPST) a accordé à un employé des options d'achat d'actions non qualifiées pour acquérir 5 400 actions dans le cadre du Plan d'Incitation 2023. Les options seront acquises sur quatre ans, avec 25% au premier anniversaire puis chaque mois par la suite, sous réserve de la poursuite de l'emploi.
Tempest Therapeutics, Inc. (Nasdaq: TPST) hat einem Mitarbeiter nicht qualifizierte Aktienoptionen zum Kauf von 5.400 Aktien im Rahmen des Anreizplans 2023 gewährt. Die Optionen werden über vier Jahre vestieren, wobei 25% am ersten Jahrestag und danach monatlich erfolgen, vorausgesetzt, das Arbeitsverhältnis besteht weiterhin.
Positive
None.
Negative
None.
BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 5,400 shares of its common stock under the Company’s 2023 Inducement Plan.
The stock options will vest over a four-year period, with 25% of each of the options vesting on the first anniversary of such employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date.
About Tempest Therapeutics Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.
How many shares were granted to an employee under Tempest Therapeutics' Inducement Plan?
One employee was granted nonqualified stock options to purchase 5,400 shares of Tempest Therapeutics' common stock.
What is the vesting period for the stock options granted?
The stock options will vest over a four-year period, with 25% vesting on the first anniversary of the employee's start date and 1/48th of the total shares vesting monthly thereafter, subject to continued employment.
What type of company is Tempest Therapeutics, Inc.?
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company developing targeted and immune-mediated therapeutics to fight cancer.
What is the stock symbol for Tempest Therapeutics?
The stock symbol for Tempest Therapeutics is TPST.
Who granted the stock options to the employee?
The Compensation Committee of the Company’s Board of Directors granted the stock options to the employee.
What is the purpose of the stock options granted?
The stock options were granted under the Company's 2023 Inducement Plan.
How will the stock options vest?
The options will vest over a four-year period, with 25% on the first anniversary of the employee's start date and 1/48th of the total shares vesting monthly thereafter.
What is the condition for vesting the stock options?
The stock options vesting is subject to the employee's continued employment on each vesting date.
tempest therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct immune response pathways relevant to mounting an effective anti-tumor response. the molecules were developed by inception sciences, a versant ventures affiliated drug discovery engine. tempest has assembled a highly experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. tempest is backed by a syndicate of leading us and china based venture capital firms.
